Kaletra (Lopinavir/Ritonavir): News
- Abbott Cuts Cost of AIDS Drug for Government Programs (May 10, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Abbott Cuts Cost of AIDS Drug for Government Programs (April 29, 2011)
In Chicago Tribune
- Lopinavir/r Oral Solution (March/April 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott (March 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- U.S. Warns Against Abbott HIV Drug in Premature Babies (March 9, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Kaletra (Lopinavir/Ritonavir) Oral Solution Label Changes Related to Toxicity in Preterm Neonates (February 24, 2011)
From U.S. Food and Drug Administration
- Once a Day Kaletra Gets Approved for Treatment Experienced, but With Caution (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Indian Government Rejects Abbott's Patent Application for Second-Line ARV (January 4, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Lopinavir/Ritonavir Approved (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- FDA Probes Risks of HIV, Prostate, Other Drugs (May 4, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Once-Daily Kaletra Dosing Approved for Treatment-Experienced Adults (April 28, 2010)
From U.S. Food and Drug Administration
- Kaletra (Lopinavir/Ritonavir) Package Insert Revision Regarding Drug-Drug Interaction Information (January 29, 2010)
From U.S. Food and Drug Administration
- FDA Warns Abbott on Magic Johnson DVD for HIV Drug (July 23, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FDA Warns Abbott on Kaletra DVD Featuring Magic Johnson (July 22, 2009)
In Reuters
- Labeling Changes for Kaletra Reflecting New QT/QTC Interval and PR Interval Prolongation Information (April 7, 2009)
HIVers who have "electrical" problems with their heart -- problems that impact their heart rhythm, for instance -- should be wary of using Kaletra (lopinavir/ritonavir), according to new information added to the drug's official labeling.
From U.S. Food and Drug Administration
- WHO Approves Heat-Stable, Generic Version of Abbott's Kaletra (February 26, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abbott Drug Pricing Condemned by AIDS Advocates in International Protests (January 27, 2009)
In coordinated actions, protesters in Mexico, Colombia and the U.S. demand that Abbott lowers the price of its key AIDS drug Kaletra; advocates otherwise vow to seek compulsory licenses in Colombia and Mexico; in U.S., AHF to also premiere 60-second video parody blasting Abbott and CEO Miles White on YouTube and place spot as TV commercial on select Chicago-area television stations.
From AIDS Healthcare Foundation
- New Pediatric Dosing Information for Kaletra, Patients 14 Days to 6 Months and 12-18 Years of Age and Update Information on Coadministration With Midazolam (PDF) (June 23, 2008)
From U.S. Food and Drug Administration
- Newly-Unsealed Documents Shed Light on Abbott Labs' 400% Norvir Price Hike (May 12, 2008)
Union, consumer groups decry Abbott for putting profits before HIV/AIDS patients' needs
In A Closer Walk: A Film by Robert Bilheimer, from Community Catalyst
- Abbott Receives FDA Approval for Lower-Dose of Kaletra for Children (November 13, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Kaletra and Accidental Overdose in Children (PDF) (August 16, 2007)
Direct Healthcare Professional communication on Kaletra (lopinavir/ritonavir) solution and accidental overdose in children.
From Abbott Laboratories
|
Advertisement
|
Email
Glossary
